JP7571037B2 - 眼表面疼痛を治療する方法 - Google Patents

眼表面疼痛を治療する方法 Download PDF

Info

Publication number
JP7571037B2
JP7571037B2 JP2021547546A JP2021547546A JP7571037B2 JP 7571037 B2 JP7571037 B2 JP 7571037B2 JP 2021547546 A JP2021547546 A JP 2021547546A JP 2021547546 A JP2021547546 A JP 2021547546A JP 7571037 B2 JP7571037 B2 JP 7571037B2
Authority
JP
Japan
Prior art keywords
compound
pain
subject
ocular
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021547546A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022520832A (ja
JPWO2020165838A5 (https=
JP2022520832A5 (https=
Inventor
メドリー，クインタス
宗人 茂木
モンテッキ－パルマー，ミケラ
スタシ，カリオピ
Original Assignee
ボシュ ＋ ロム アイルランド リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ボシュ ＋ ロム アイルランド リミテッド filed Critical ボシュ ＋ ロム アイルランド リミテッド
Publication of JP2022520832A publication Critical patent/JP2022520832A/ja
Publication of JPWO2020165838A5 publication Critical patent/JPWO2020165838A5/ja
Publication of JP2022520832A5 publication Critical patent/JP2022520832A5/ja
Priority to JP2024177283A priority Critical patent/JP2025004186A/ja
Application granted granted Critical
Publication of JP7571037B2 publication Critical patent/JP7571037B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021547546A 2019-02-15 2020-02-13 眼表面疼痛を治療する方法 Active JP7571037B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024177283A JP2025004186A (ja) 2019-02-15 2024-10-09 眼表面疼痛を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962806682P 2019-02-15 2019-02-15
US62/806,682 2019-02-15
PCT/IB2020/051210 WO2020165838A1 (en) 2019-02-15 2020-02-13 Methods for treating ocular surface pain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024177283A Division JP2025004186A (ja) 2019-02-15 2024-10-09 眼表面疼痛を治療する方法

Publications (4)

Publication Number Publication Date
JP2022520832A JP2022520832A (ja) 2022-04-01
JPWO2020165838A5 JPWO2020165838A5 (https=) 2023-02-21
JP2022520832A5 JP2022520832A5 (https=) 2023-02-21
JP7571037B2 true JP7571037B2 (ja) 2024-10-22

Family

ID=69740423

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021547546A Active JP7571037B2 (ja) 2019-02-15 2020-02-13 眼表面疼痛を治療する方法
JP2024177283A Pending JP2025004186A (ja) 2019-02-15 2024-10-09 眼表面疼痛を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024177283A Pending JP2025004186A (ja) 2019-02-15 2024-10-09 眼表面疼痛を治療する方法

Country Status (17)

Country Link
US (4) US20200261456A1 (https=)
EP (1) EP3923909A1 (https=)
JP (2) JP7571037B2 (https=)
KR (1) KR20210129677A (https=)
CN (1) CN113453686B (https=)
AU (2) AU2020222348B2 (https=)
BR (1) BR112021015998A2 (https=)
CA (1) CA3130038A1 (https=)
CL (1) CL2021002152A1 (https=)
IL (1) IL284629A (https=)
JO (1) JOP20210217A1 (https=)
MX (2) MX2021009702A (https=)
PH (1) PH12021551968A1 (https=)
SG (1) SG11202107260VA (https=)
TW (2) TW202515576A (https=)
WO (1) WO2020165838A1 (https=)
ZA (1) ZA202104593B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
WO2022029656A1 (en) * 2020-08-06 2022-02-10 Novartis Ag Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof
CN119184616A (zh) * 2024-09-03 2024-12-27 中山大学附属第三医院粤东医院(梅州市梅县区人民医院) 一种疼痛等级的测评方法及其评估系统

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501763A (ja) 2004-06-08 2008-01-24 ノバルティス アクチエンゲゼルシャフト バニロイドアンタゴニストとして有用なキナゾリノン誘導体
JP2012515150A (ja) 2009-01-13 2012-07-05 ノバルティス アーゲー バニロイドアンタゴニストとして有用なキナゾリノン誘導体
JP2013528382A (ja) 2010-05-27 2013-07-11 シレンティス・エセ・ア・ウ 眼の状態の治療および／または予防のための方法および組成物におけるｓｉＲＮＡおよびそれらの使用
WO2017132115A1 (en) 2016-01-25 2017-08-03 Jenivision Inc. Use of prostacyclin antagonists for treating ocular surface nociception
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
JP2022520410A (ja) 2019-02-15 2022-03-30 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの結晶形態及びその製剤

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1280874B (de) 1963-10-09 1968-10-24 Boehringer Sohn Ingelheim 2-Methyl-3-(2-dimethylaminophenyl)-8-amino-3H-chinazolon-(4)
US7893260B2 (en) 2005-11-04 2011-02-22 Hydra Biosciences, Inc. Substituted quinazolin-4-one compounds for antagonizing TRPV3 function
GB0525069D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
BRPI0620264A2 (pt) 2005-12-22 2011-11-08 Prolexys Pharmaceuticals Inc quinazolonas aril-substituìdas e sua utilização
TW200738232A (en) 2006-01-31 2007-10-16 Alcon Mfg Ltd Use of vanilloid receptor-1 antagonists for the prevention and treatment of glaucoma
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
AR067631A1 (es) 2007-07-18 2009-10-21 Novartis Ag Combinaciones sinergicas de antagonistas de vr-1 e inhibidores de cox-2 , composicion farmaceutica y uso
TW200927192A (en) * 2007-11-19 2009-07-01 Alcon Res Ltd Use of TRPV1 receptor antagonists for treating dry eye and ocular pain
WO2009081222A1 (en) 2007-12-21 2009-07-02 Glenmark Pharmaceuticals, S.A. Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands
CA2707441A1 (en) 2008-01-09 2009-07-16 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2009090548A2 (en) 2008-01-17 2009-07-23 Glenmark Pharmaceuticals, S.A. 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands
WO2009149239A1 (en) 2008-06-04 2009-12-10 Children's Medical Center Corporation Methods of modulating angiogenesis via trpv4
WO2010023512A1 (en) 2008-08-28 2010-03-04 Matrix Laboratories Ltd. Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them
EP2316420B1 (en) 2009-10-22 2014-02-26 Consorzio Universitario Unifarm Topical ophthalmic composition to reduce pain
EP2377850A1 (en) 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
EP2627178B1 (en) 2010-10-11 2018-05-02 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
CN102875480A (zh) 2012-04-23 2013-01-16 中国药科大学 喹唑啉酮类血管抑制剂、其制备方法及其医药用途
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
US10590077B2 (en) 2016-09-20 2020-03-17 Glaxosmithkline Intellectual Property Development Limited TRPV4 antagonists
CN109790116B (zh) 2016-09-20 2022-10-28 葛兰素史密斯克莱知识产权（第2 号）有限公司 Trpv4拮抗剂
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產（第二）有限公司 Ｔｒｐｖ４拮抗劑

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501763A (ja) 2004-06-08 2008-01-24 ノバルティス アクチエンゲゼルシャフト バニロイドアンタゴニストとして有用なキナゾリノン誘導体
JP2012515150A (ja) 2009-01-13 2012-07-05 ノバルティス アーゲー バニロイドアンタゴニストとして有用なキナゾリノン誘導体
JP2013528382A (ja) 2010-05-27 2013-07-11 シレンティス・エセ・ア・ウ 眼の状態の治療および／または予防のための方法および組成物におけるｓｉＲＮＡおよびそれらの使用
WO2017132115A1 (en) 2016-01-25 2017-08-03 Jenivision Inc. Use of prostacyclin antagonists for treating ocular surface nociception
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
JP2022017260A (ja) 2019-02-15 2022-01-25 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
JP2022520410A (ja) 2019-02-15 2022-03-30 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの結晶形態及びその製剤
JP2022520795A (ja) 2019-02-15 2022-04-01 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
4-(7-HYDROXY-2-ISOPROPYL-4-OXOQUINAZOLIN-3(4H)-YL)BENZONITRILE，PUBCHEM CID 25138363，2020年04月21日，PAGE(S):1-13，https://pubchem.ncbi.nlm.nih.gov/compound/25138363
A randomized, vehicle-controlled, subject and investigator-masked, proof-of-concept study to evaluate the use of topical ocular SAF312 in the treatment of postoperative ocular pain in patients udergoing photorefractive keratectomy (PRK) surgery，[ONLINE]，2017年04月11日，PAGE(S):1-72，https://clinicaltrials.gov/ProvidedDocs/62/NCT02961062/Prot_000.pdf
A randomized, vehicle-controlled, subject and investigator-masked, proof-of-concept study to evaluate the use of topical ocular SAF312 in the treatment of postoperative ocular pain in patients udergoing photorefractive keratectomy (PRK) surgery，[ONLINE]，2018年03月22日，PAGE(S):1-14，https://clinicaltrials.gov/ProvidedDocs/62/NCT02961062/SAP_001.pdf

Also Published As

Publication number Publication date
AU2020222348A1 (en) 2021-08-05
BR112021015998A2 (pt) 2021-10-05
ZA202104593B (en) 2025-03-26
JP2022520832A (ja) 2022-04-01
JP2025004186A (ja) 2025-01-14
IL284629A (en) 2021-08-31
US20210275529A1 (en) 2021-09-09
TW202515576A (zh) 2025-04-16
CN113453686A (zh) 2021-09-28
PH12021551968A1 (en) 2022-05-23
TW202045179A (zh) 2020-12-16
WO2020165838A9 (en) 2021-03-18
KR20210129677A (ko) 2021-10-28
AU2023203716B2 (en) 2025-03-20
US20220193078A1 (en) 2022-06-23
MX2021009702A (es) 2021-09-14
SG11202107260VA (en) 2021-08-30
US20240342174A1 (en) 2024-10-17
TWI878266B (zh) 2025-04-01
MX2025000353A (es) 2025-02-10
EP3923909A1 (en) 2021-12-22
CN113453686B (zh) 2025-04-15
US11234982B2 (en) 2022-02-01
JOP20210217A1 (ar) 2023-01-30
WO2020165838A1 (en) 2020-08-20
AU2020222348B2 (en) 2023-03-16
CL2021002152A1 (es) 2022-04-18
US20200261456A1 (en) 2020-08-20
CA3130038A1 (en) 2020-08-20
AU2023203716A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
JP7465453B2 (ja) ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
AU2023203716B2 (en) Methods for treating ocular surface pain
RU2850452C2 (ru) Способы лечения боли на поверхности глаза
KR20260057219A (ko) 4-(7-히드록시-2-이소프로필-4-옥소-4h-퀴나졸린-3-일)-벤조니트릴의제형

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240123

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240723

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241009

R150 Certificate of patent or registration of utility model

Ref document number: 7571037

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150